Core B - Clinical Core

临床核心项目总结/摘要 临床核心的使命与整个MADRC的使命相似：支持对病因的研究， AD和相关痴呆的机制和治疗，最终目标是治愈甚至预防 这些紊乱。当1984年首次成立时，我们的大部分工作都集中在AD上，从AD痴呆开始 并扩展为轻度认知障碍（MCI）。在过去的5年里， 在核心开发了血管性认知障碍，帕金森病， 痴呆/路易体痴呆和额颞叶痴呆。我们现在将核心的重点进一步扩展到 强调有痴呆风险的正常老年人和那些主观上患有痴呆症的人的行为和生物特征， 认知问题。为了促进这些领域的临床研究，我们建立并维持了一个 纵向队列（LC）的男性和女性来自不同的民族和种族背景，涵盖了整个范围 认知功能从正常到主观抱怨到轻度认知障碍再到痴呆。全面系统 对该队列的检查是临床核心使命的核心。从这个特征鲜明的纵向 随访队列，我们向NACC提供及时准确的数据提交;国家多中心受试者 研究，如ADNI，DIAN和ADCS试验;以及用于遗传和生物标志物研究的生物样品。的 LC还推动我们中心的本地研究：我们将继续支持40多项研究， 我们的评估和我们的主题，他们的数据和/或他们的生物液体成功，包括项目1和2 在这次更新申请中。特别强调我们的核心，符合我们中心的理解和 认识到疾病的最早阶段，是发展新的评估工具，可用于我们的 和其他人在这方面的研究。我们还将致力于将受试者转介到新的神经成像核心， 支持外展核心中的新招募登记处，并与神经病理学协调 核心是为了顺利进行尸检。核心将与外联核心一起提高认识 关于AD和痴呆症，并协助增加获得LC的少数民族受试者的数量， 研究项目。核心的最终目标是帮助培训下一代调查人员，我们将继续 吸引有前途的临床科学家，并为他们的职业发展提供激励环境。

CLINICAL CORE PROJECT SUMMARY/ABSTRACT The mission of the Clinical Core parallels that of the MADRC as a whole: To support research into the causes, mechanisms and treatment of AD and related dementias, with the eventual goal of curing and even preventing these disorders. When first established in 1984, much of our work centered on AD, beginning with AD dementia and expanding to Mild Cognitive Impairment (MCI). The focus broadened over the past 5 years as investigators in the Core developed specific research programs in vascular cognitive impairment, Parkinson disease dementia/dementia with Lewy bodies, and frontotemporal dementia. We now expand our Core's focus further to emphasize the behavioral and biological features of normal elders at risk for dementia and those with subjective cognitive concerns. In order to facilitate clinical research in these areas, we have established and maintain a Longitudinal Cohort (LC) of men and women from diverse ethnic and racial backgrounds spanning a full range of cognitive function from normal to subjective complaints to MCI to dementia. Comprehensive and systematic examination of this cohort is central to the Clinical Core mission. From this well-characterized and longitudinally followed cohort, we provide timely and accurate data submission to NACC; subjects for national multi-center studies such as ADNI, DIAN and ADCS trials; and biological samples for genetic and biomarker research. The LC also fuels our Center's local research studies: we will continue to support the more than 40 studies that rely on our evaluations and our subjects, their data and/or their biologic fluids for success, including Projects 1 and 2 in this renewal application. A special emphasis of our Core, in line with our Center's theme of understanding and recognizing the earliest phase of disease, is the development of novel assessment tools that can be used in our and others' studies in this area. We will also work on referring subjects to the new Neuroimaging Core, on supporting the new Recruitment Registry in the Outreach Core, and on coordinating with the Neuropathology Core to facilitate smooth autopsy protocols. The Core will join with the Outreach Core in raising awareness about AD and dementias, and assist in increasing the number of minority subjects who have access to LC and research projects. A final goal of the Core is help train the next generation of investigators, and we will continue to attract promising clinician-scientists and provide a stimulating environment for their career development.